Department of Medicine, Austin Health, University of Melbourne, Level 7, Lance Townsend Building, 145 Studley Road, Melbourne, VIC 3084, Australia.
Cardiovasc Diabetol. 2012 Apr 26;11:42. doi: 10.1186/1475-2840-11-42.
Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF -945 G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis. This study investigated the association of the CTGF -945 G/C promoter variant with cardiac complications (left ventricular (LV) hypertrophy (LVH), diastolic and systolic dysfunction) and chronic kidney disease (CKD) in type 2 diabetes.
The CTGF -945 G/C polymorphism (rs6918698) was examined in 495 Caucasian subjects with type 2 diabetes. Cardiac structure and function were assessed by transthoracic echocardiography. Kidney function was assessed using estimated glomerular filtration rate (eGFR) and albuminuria, and CKD defined as the presence of kidney damage (decreased kidney function (eGFR <60 ml/min/1.73 m2) or albuminuria).
The mean age ± SD of the cohort was 62 ± 14 years, with a body mass index (BMI) of 31 ± 6 kg/m2 and median diabetes duration of 11 years [25th, 75th interquartile range; 5, 18]. An abnormal echocardiogram was present in 73% of subjects; of these, 8% had LVH alone, 74% had diastolic dysfunction and 18% had systolic ± diastolic dysfunction. CKD was present in 42% of subjects. There were no significant associations between the CTGF -945 G/C polymorphism and echocardiographic parameters of LV mass or cardiac function, or kidney function both before and after adjustment for covariates of age, gender, BMI, blood pressure and hypertension. CTGF -945 genotypes were not associated with the cardiac complications of LVH, diastolic or systolic dysfunction, nor with CKD.
In Caucasians with type 2 diabetes, genetic variation in the CTGF -945 G/C polymorphism is not associated with cardiac or kidney complications.
结缔组织生长因子 (CTGF) 与 2 型糖尿病的心脏和肾脏并发症有关，CTGF-945G/C 多态性与系统性硬化症（一种以组织纤维化为特征的疾病）的易感性有关。本研究探讨了 CTGF-945G/C 启动子变异与 2 型糖尿病患者心脏并发症（左心室肥厚 (LVH)、舒张和收缩功能障碍）和慢性肾脏病 (CKD) 的关系。
在 495 名白人 2 型糖尿病患者中检测了 CTGF-945G/C 多态性（rs6918698）。通过经胸超声心动图评估心脏结构和功能。通过估计肾小球滤过率 (eGFR) 和白蛋白尿评估肾功能，并且将 CKD 定义为存在肾脏损伤（肾功能下降 (eGFR <60ml/min/1.73m2) 或白蛋白尿）。
该队列的平均年龄 ± 标准差为 62 ± 14 岁，体重指数 (BMI) 为 31 ± 6kg/m2，中位糖尿病病程为 11 年[25%，75% 四分位间距；5,18]。73%的受试者存在异常超声心动图；其中，8%仅存在 LVH，74%存在舒张功能障碍，18%存在收缩期±舒张功能障碍。42%的受试者存在 CKD。CTGF-945G/C 多态性与 LV 质量或心脏功能的超声心动图参数或调整年龄、性别、BMI、血压和高血压等混杂因素前后的肾功能均无显著相关性。CTGF-945 基因型与 LVH、舒张或收缩功能障碍等心脏并发症以及 CKD 均无相关性。
在 2 型糖尿病的白种人群中，CTGF-945G/C 多态性的遗传变异与心脏或肾脏并发症无关。
